Ip immunotherapy and chemotherapy in advanced epithelial ovarian cancer.
Nine patients with advanced epithelial ovarian cancer, classified as either stage III with macrometastatic residual disease or stage IV, received combination chemotherapy in conjunction with ip rabbit-derived human ovarian antitumor serum (HOATS). The HOATS regimen consisted of the ip instillation of 100 ml of ovarian antitumor serum on Days 1 and 3 of the first chemotherapy cycle. Side effects attributable to HOATS were low-grade fever in three patients and diffuse skin rash in two. The 1-year cumulative survival was 87%, with a clinical response rate of 80%. No significant toxic reactions to HOATS have been observed. Continuation of the present study seems justified.
D000230:Adenocarcinoma / Q000628:therapy*; D000912:Antibodies, Neoplasm / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003872:Dermatitis / Q000209:etiology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005334:Fever; D006801:Humans; D007167:Immunotherapy; D007274:Injections, Intraperitoneal; D010051:Ovarian Neoplasms / Q000628:therapy*
D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents